MC1635 3期试验:保乳术后超低分割与中度低分割辅助放疗的医生报告和患者报告结局
MC1635 3期随机试验纳入107例保乳术后局限期乳腺癌患者,比较40 Gy/15次中度低分割与25 Gy/5次超低分割全乳放疗,中位随访42.8个月,两组晚期毒性及医生评分美容效果相似,患者报告美容效果仅在3个月时MHF组优于UHF组。
要点
- 两组均未观察到3级及以上毒性。
- 医生评估美容效果恶化在两组间无显著差异。
- 患者报告美容效果在3个月时MHF组优于UHF组,但1、2、3年时差异消失。
核心结论
- 保乳术后辅助全乳放疗中,超低分割(25 Gy/5次)与中度低分割(40 Gy/15次)相比,治疗相关晚期毒性和医生评分美容效果相似。
研究设计与样本
- 3期随机临床试验,2018年2月至2020年2月纳入107例保乳术后局限期乳腺癌患者(pT0-3 pN0-1 M0),随机分配至中度低分割组(MHF,n=54)或超低分割组(UHF,n=53),可选同步整合推量,中位随访42.8个月。
主要发现
- 治疗结束时2级放射性皮炎MHF组4例(7.4%) vs UHF组2例(3.7%)(P = .726),未观察到3级及以上毒性。
- 治疗结束时医生评估美容效果恶化UHF组2例(6.7%) vs MHF组1例(1.9%)(P = .534),3个月时仅MHF组1例(1.8%)出现恶化(P = .315)。
- 治疗结束时患者报告美容效果极好/好MHF组91% vs UHF组94%(P = .550),3个月时MHF组100% vs UHF组91%(P = .030),但1、2、3年时差异消失。
关键数值与推荐
- MHF方案为40 Gy分15次,UHF方案为25 Gy分5次,均可选同步整合推量;毒性、美容效果和生活质量在基线、治疗结束、3个月、1年、2年和3年时评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our aim was to report physician- and patient-reported outcomes of patients with localized breast cancer treated with moderate versus ultrahypofractionated whole breast irradiation (WBI) after breast-conserving surgery (BCS). METHODS AND MATERIALS: Between February 2018 and February 2020, patients with localized breast cancer (pT0-3 pN0-1 M0) were offered participation in a phase 3 randomized clinical trial assessing adjuvant moderate hypofractionation (MHF) to 40 Gy in 15 fractions versus ultrahypofractionation (UHF) to 25 Gy in 5 fractions after BCS, with an optional simultaneously integrated boost. Toxicities, cosmesis, and quality of life were assessed at baseline, end of treatment (EOT), and 3 months, 1 year, 2 years, and 3 years from irradiation using validated metric tools. RESULTS: One hundred seven patients were randomized to MHF (n = 54) or UHF (n = 53) adjuvant WBI. The median follow-up was 42.8 months. Grade 2 radiation dermatitis was experienced by 4 patients (7.4%) in the MHF arm and 2 patients (3.7%) in the UHF arm at EOT (P = .726). No grade 3 or higher toxicities were observed. Deterioration of cosmesis by physician assessment was observed in 2 (6.7%) patients treated in the UHF arm and 1 (1.9%) patient treated in the MHF arm at EOT (P = .534), whereas at 3 months, only 1 (1.8%) patient treated in the MHF arm demonstrated deterioration of cosmesis (P = .315). At EOT, 91% and 94% of patients reported excellent/good cosmesis among those treated with MHF and UHF regimens, respectively (P = .550). At 3 months, more patients within the MHF arm reported excellent/good cosmesis compared with those in the UHF arm (100% vs 91%; P = .030). However, the difference in patient-reported cosmesis disappeared at the 1-, 2-, and 3-year time points. CONCLUSIONS: UHF WBI showed similar treatment-related late toxicities and similar provider-scored cosmesis compared with MHF radiation in patients treated adjuvantly after BCS.
引用
- Laughlin BS, Corbin KS, Toesca DAS, et al. Physician- and Patient-Reported Outcomes of the MC1635 Phase 3 Trial of Ultrahypofractionated Versus Moderately Hypofractionated Adjuvant Radiation Therapy After Breast-Conserving Surgery. Int J Radiat Oncol Biol Phys. 2023. PMID: 37914139. doi:10.1016/j.ijrobp.2023.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。